Search clinical trials for: AZD2423

Total 39 results

AstraZeneca

Completed

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Germany
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers (ADME)

Neuroscience

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers

Healthy

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers (SAD)

Healthy Volunteers

Germany
AstraZeneca

Completed

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

Neuropathic Pain

United States, Canada
AstraZeneca

Completed

AZD6423 SAD/MAD Study in Healthy Volunteers (AZD6423)

Healthy Volunteers.

United States
AstraZeneca

Completed

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..

Nerve Pain

Sweden, Bulgaria, France, Russian Federation, United Kingdom, Poland, Denmark
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers

Healthy

Japan
AstraZeneca

Completed

AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy Volunteer

United Kingdom
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
AstraZeneca

Completed

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

Healthy

United States
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan
AstraZeneca

Terminated

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

Obesity

United Kingdom
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
AstraZeneca
Parexel

Withdrawn

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

Heart Failure
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Heart Failure

United States
AstraZeneca

Completed

To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses

Healthy

United Kingdom
AstraZeneca

Completed

AZD2624 Multiple Ascending Dose Study in Japan (JMAD)

Healthy | Safety

Japan
AstraZeneca
Parexel

Recruiting

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (Re-PHIRE)

Heart Failure | Pulmonary Hypertension (World Health Organization Group 2)

Netherlands, Spain, Japan, Germany, Austria, Italy, China, Sweden, United Kingdom, United States, Poland, Czechia, Denmark, Canada
AstraZeneca

Completed

A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients

Arrhythmia

Sweden, Norway
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

Healthy

Sweden
AstraZeneca
Parexel

Completed

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Metabolic Disorders | Non-alcoholic Steatohepatitis

United States
AstraZeneca

Completed

A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Healthy | Asthma

United Kingdom
AstraZeneca

Completed

An Open-Label, Dose-Escalation Study of AZD2461

Refractory Solid Tumors | Cancer Tumor

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

Healthy Participants

Japan
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca

Completed

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Anxious Major Depressive Disorder

United States
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

Nonalcoholic Steatohepatitis

United States, China, Korea, Republic of, Germany, Japan, Spain, Vietnam, Argentina, Colombia, Peru, Brazil, Malaysia, Taiwan, Thailand, Italy, Turkey, Hong Kong, Singapore, India, Mexico, Chile, Philippines, Portugal
AstraZeneca
Parexel

Completed

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Healthy Volunteers

United States
AstraZeneca
Parexel

Completed

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Healthy Volunteers

United States
Cancer Research UK

Terminated

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (AZD0424)

Advanced Solid Tumours

United Kingdom
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca

Completed

Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, France, Italy, Poland, Russian Federation, Ukraine, Hungary, Slovakia
AstraZeneca

Completed

The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen (Allergen)

Asthma

Canada
AstraZeneca

Completed

Phase IIA Study in Patients With Schizophrenia

Schizophrenia

United States

3

Subscribe